Topically applied (not injected) H100™ is most effective when used in the acute phase of the disease, though it can be utilized in all stages. It is based on Hybrid Medical’s advancement in sub-dermal treatment delivery.
A proprietary and patented combination of plaque-modifying ingredients and an effective transdermal carrier delivers medicine directly into the area of scar tissue. Research shows the ingredients disrupt the inflammatory process and remodel scar tissue which may reduce curvature and pain.1
- Oil from the emu bird native to Australia
- Historically used by Aborigines to treat burns, wounds and scar tissue
- Shown to be an extremely effective transdermal carrier2
- May have anti-inflammatory and scar remodeling properties3 4
- Shown to be clinically effective when injected into Peyronie’s disease tissue5
Superoxide Dismutase (SOD)
- Used to treat inflammatory and other diseases
- Topically applied SOD has been shown to be effective in Peyronie’s disease studies6
Abstract of Our Published Clinical Study Results
Int J Impot Res. 2016 Mar-Apr;28(2):41-5. doi: 10.1038/ijir.2015.22. Epub 2015 Dec 24.
Topical treatment for acute phase Peyronie’s disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study.
Twidwell J, Levine L.
Safety and efficacy of topically applied gel H-100 composed of Nicardipine, superoxide dismutase and emu oil for treatment of acute phase Peyronie’s disease (PD) was evaluated. Twenty-two patients (PD <12 months duration) were studied in a prospective, randomized, double-blind, placebo-controlled study. Eleven patients received H-100 and 11 patients received placebo for 3 months. All 22 patients then received H-100 for the final 3 months. Flaccid-stretched penile length, degree of penile curvature, pain level and side effects were assessed monthly. H-100 showed significant improvement in all PD parameters at 6 months: mean stretched penile length increase (22.6%, P=0.0002), mean curvature reduction (40.8%, P=0.0014), and mean pain level reduction (85.7%, P=0.004). Placebo group showed no significant improvement except for mean stretched penile length increase (6.8%, P=0.009). Crossover patients from placebo to H-100 showed significant improvement in all parameters: mean stretched penile length increase (17.5%, P=0.000007), mean curvature reduction (37.1%, P=0.006), and mean pain level reduction (40%, P=0.17). Treatment was well tolerated. A self-limited rash was the only side effect in three patients. Statistically significant improvements in flaccid-stretched penile length, curvature and pain suggest that H-100 is a safe and possibly effective non-invasive, topically applied treatment for acute phase Peyronie's Disease.
Based on our study, maximum benefit was seen after six months of treatment with H100™, though many patients noted improvement after three months of treatment.1
Important Note: H100™ gel is only meant to be applied topically as directed for treatment of Peyronie’s disease. It is not intended for any other use. Do NOT take it orally, by injection or through any other method of delivery. For best results, always follow prescribing directions carefully.
6. Riedl C, Sternig P, Galle G, Langmann F, Vcelar B, Vorauer K et al. Liposomal recombinant human superoxide dismutase for the treatment of Peyronie’s disease: a randomized placebo-controlled double-blind prospective clinical study. Eur Urol 2005; 48: 656–661.